HMG-CoA reductase inhibitors improve acute ischemic stroke outcome
Department of Neurology
Aged; Brain Ischemia; Cerebral Hemorrhage; Cerebrovascular Disorders; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Recurrence; Regression Analysis; Risk; Severity of Illness Index; Stroke; Treatment Outcome
Neurology | Neuroscience and Neurobiology
BACKGROUND AND PURPOSE: Statins reduce the risk of stroke recurrence, but the benefits of statins in improving outcome of acute stroke patients have not been well explored.
METHODS: We assessed potential effects of statins initiated before or within 4 weeks of stroke on 90-day outcome. Favorable outcomes were National Institutes of Health Stroke Scale (NIHSS) score < or =2 at 12 weeks and modified Rankin Scale (mRS) < or =2.
RESULTS: Before stroke, 129 patients were receiving statins, 123 initiated statins within 4 weeks, and 600 patients were not on statins. Multivariate logistic regression analysis demonstrated that poststroke statins were associated with a significant probability of a favorable outcome at 12 weeks [NIHSS (P=0.002; OR, 1.92; CI, 1.27 to 2.91) and mRS (P=0.033; OR, 1.57; CI, 1.04 to 2.38)], whereas prestroke statins demonstrated a trend toward significance.
CONCLUSIONS: These preliminary results suggest that statin use may improve outcome of acute ischemic stroke.
DOI of Published Version
Stroke. 2005 Jun;36(6):1298-300. Epub 2005 May 5. Link to article on publisher's site
Stroke; a journal of cerebral circulation
Moonis M, Kane KJ, Schwiderski U, Sandage BW, Fisher M. (2005). HMG-CoA reductase inhibitors improve acute ischemic stroke outcome. Neurology Publications. https://doi.org/10.1161/01.STR.0000165920.67784.58. Retrieved from https://escholarship.umassmed.edu/neuro_pp/60